TKTed Kwaks

Ted Kwaks

*This is an algorithmically generated author record based on publicly available information.

Ted Kwaks has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Boerries Brandenburg

    Janssen Vaccines & Prevention, Leiden, the Netherlands

    6 shared publications
  • Ronald Vogels

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, Netherlands

    6 shared publications
  • Robert H. E. Friesen

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, Netherlands

    5 shared publications
  • Hans J. W. M. Korse

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, Netherlands

    4 shared publications
  • Jaap Goudsmit

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, Netherlands

    4 shared publications
  • Wouter Koudstaal

    Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice

    by Joan E. M. van der Lubbe, Johan W. A. Verspuij, Jeroen Huizingh, Sonja P. R. Schmit-Tillemans, Jeroen T. B. M. Tolboom, Liesbeth E. H. A. Dekking, Ted Kwaks, Börries Brandenburg, Wim Meijberg, Roland C. Zahn, et al.

    Seasonal influenza vaccines are updated almost annually to match the antigenic drift in influenza hemagglutinin (HA) surface glycoprotein. A new HA stem-based antigen, the so-called “mini-HA,” was recently shown to induce cross-protective antibodies. However, cross-reactive antibodies targeting the HA stem can also be found in mice and humans after administration of seasonal vaccine. This has raised the question whether in similar conditions such a mini-HA would be able to show an increased breadth of protection over immunization with full length (FL) HA. We show in mice that in a direct comparison to H1 FL HA, using the same immunization regimen, dosing and adjuvant, a group 1 mini-HA has a higher protective efficacy against group 1 influenza virus challenges not homologous to the H1 FL HA. Although both antigens induce a similar breadth of HA subtype binding, mini-HA immunization induces significantly more HA stem-specific antibodies correlating with survival. In addition, both mini-HA and H1 FL HA immunization induce influenza neutralizing antibodies while mini-HA induces significantly higher levels of mFcγRIII activation, involved in Fc-mediated antibody effector functions. In agreement with previous findings, this confirms that more than one mechanism contributes to protection against influenza. Together our results further warrant the development of a universal influenza vaccine based on the HA stem region.


  • Open Access

    Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge

    by Joan E. M. van der Lubbe, Jeroen Huizingh, Johan W. A. Verspuij, Lisanne Tettero, Sonja P. R. Schmit-Tillemans, Petra Mooij, Daniella Mortier, Gerrit Koopman, Willy M. J. M. Bogers, Liesbeth Dekking, et al.

    Seasonal vaccines are currently the most effective countermeasure against influenza. However, seasonal vaccines are only effective against strains closely related to the influenza strains contained in the vaccine. Recently a new hemagglutinin (HA) stem-based antigen, the so-called “mini-HA”, has been shown to induce a cross-protective immune response in influenza-naive mice and non-human primates (NHP). However, prior exposure to influenza can have a profound effect on the immune response to subsequent influenza infection and the protective efficacy of vaccination. Here we show that mini-HA, compared to a trivalent influenza vaccine (TIV), elicits a broadened influenza-specific humoral immune response in NHP previously exposed to influenza. Serum transfer experiments showed that antibodies induced by both mini-HA and seasonal vaccine protected mice against lethal challenge with a H1N1 influenza strain heterologous to the H1 HA included in the TIV. However, antibodies elicited by mini-HA showed an additional benefit of protecting mice against lethal heterosubtypic H5N1 influenza challenge, associated with H5 HA-specific functional antibodies.


  • Open Access

    HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids

    by Freek Cox, Ted Kwaks, Boerries Brandenburg, Martin H. Koldijk, Vincent Klaren, Bastiaan Smal, Hans J. W. M. Korse, Eric Geelen, Lisanne Tettero, David Zuijdgeest, et al.

    Interactions with receptors for the Fc region of IgG (FcγRs) have been shown to contribute to the in vivo protection against influenza A viruses provided by broadly neutralizing antibodies (bnAbs) that bind to the viral hemagglutinin (HA) stem. In particular, Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) has been shown to contribute to protection by stem-binding bnAbs. Fc-mediated effector functions appear not to contribute to protection provided by strain-specific HA head-binding antibodies. We used a panel of anti-stem and anti-head influenza A and B monoclonal antibodies with identical human IgG1 Fc domains and investigated their ability to mediate ADCC associated FcγRIIIa activation. Antibodies which do not interfere with sialic acid binding of HA can mediate FcγRIIIa activation. However, the FcγRIIIa activation was inhibited when a mutant HA, unable to bind sialic acids, was used. Antibodies which block sialic acid receptor interactions of HA interfered with FcγRIIIa activation. The inhibition of FcγRIIIa activation by HA head-binding and sialic acid receptor blocking antibodies was confirmed in plasma samples of H5N1 vaccinated human subjects. Together, these results suggest that in addition to Fc–FcγR binding, interactions between HA and sialic acids on immune cells are required for optimal Fc-mediated effector functions by anti-HA antibodies.


  • Open Access

    Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level

    by Jason J. Otterstrom, Boerries Brandenburg, Martin H. Koldijk, Jarek Juraszek, Chan Tang, Samaneh Mashaghi, Ted Kwaks, Jaap Goudsmit, Ronald Vogels, Robert H. E. Friesen, et al.

    Significance: We determine the number of broadly neutralizing antibodies required to inhibit influenza virus membrane fusion by simultaneously observing individual viral particles undergoing fusion and counting the number of antibodies bound to them. The viral membrane fusion process is mediated by fusion proteins whose activity is blocked through the binding of these antibodies to evolutionarily conserved epitopes. Surprisingly, the number of antibodies required for inhibition is markedly lower than the number of fusion proteins present, indicating virus neutralization does not require saturation of epitope occupancy. Overall, our results support a model of membrane fusion requiring several fusion proteins working together in a coordinated, stochastic fashion, and the inhibition of this process through disruption of fusion protein coordination.


  • Open Access

    Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization

    by Boerries Brandenburg, Wouter Koudstaal, Jaap Goudsmit, Vincent Klaren, Chan Tang, Miriam V. Bujny, Hans J. W. M. Korse, Ted Kwaks, Jason J. Otterstrom, Jarek Juraszek, et al.

    Human monoclonal antibodies have been identified which neutralize broad spectra of influenza A or B viruses. Here, we dissect the mechanisms by which such antibodies interfere with infectivity. We distinguish four mechanisms that link the conserved hemagglutinin (HA) epitopes of broadly neutralizing antibodies to critical processes in the viral life cycle. HA-stem binding antibodies can act intracellularly by blocking fusion between the viral and endosomal membranes and extracellularly by preventing the proteolytic activation of HA. HA-head binding antibodies prevent viral attachment and release. These insights into newly identified ways by which the human immune system can interfere with influenza virus infection may aid the development of novel universal vaccines and antivirals.


  • A common solution to group 2 influenza virus neutralization

    by Robert H. E. Friesen, Peter S. Lee, Esther J. M. Stoop, Ryan M. B. Hoffman, Damian C. Ekiert, Gira Bhabha, Wenli Yu, Jarek Juraszek, Wouter Koudstaal, Mandy Jongeneelen, et al.

    Significance: The HA surface glycoprotein on influenza A viruses mediates viral entry into host cells. HA is highly variable and classified into 18 divergent subtypes, which cluster into two major phylogenetic groups. Antibody CR8043 has heterosubtypic neutralizing activity against group 2 viruses, including H3 viruses that currently circulate in humans. X-ray and EM structures of CR8043 Fab in complex with H3 HAs reveal that the antibody targets a conserved epitope on the HA stem. Compared with CR8020, the only other structurally characterized group 2 neutralizing antibody, CR8043 binds to HA with a different approach angle using different contact residues. The epitopes of both antibodies are very similar, which suggests that this conserved stem epitope has great potential for design of therapeutics and vaccines.


  • Top Cited Papers

    Highly Conserved Protective Epitopes on Influenza B Viruses

    by Cyrille Dreyfus, Nick S. Laursen, Ted Kwaks, David Zuijdgeest, Reza Khayat, Damian C. Ekiert, Jeong Hyun Lee, Zoltan Metlagel, Miriam V. Bujny, Mandy Jongeneelen, et al.

    Influenza Antibodies, Part B: With its ability to reassort in animal hosts like pigs and birds, and to cause pandemics, influenza A viruses are often in the spotlight. However, a substantial portion of the annual flu burden is also the result of influenza B virus, which is a single influenza type that is characterized by two antigenically and genetically distinct lineages. Dreyfus et al. (p. 1343 , published online 9 August) identify three monoclonal human antibodies that are able to protect against lethal infection with both lineages of influenza B virus in mice. Two antibodies, which bind to distinct regions of the viral hemagluttinin (HA) molecule, neutralize multiple strains from both lineages of influenza B virus, whereas the third antibody binds to the stem region of HA and is able to neutralize both influenza A and B strains. The structural data from these antibodies bound to HA, together with already known antibodies targeting influenza A, may provide clues for designing a universal vaccine to protect against both influenza virus types.


  • Top Cited Papers

    A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

    by Damian C. Ekiert, Robert H. E. Friesen, Gira Bhabha, Ted Kwaks, Mandy Jongeneelen, Wenli Yu, Carla Ophorst, Freek Cox, Hans J.W.M. Korse, Boerries Brandenburg, et al.

    Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of VH1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.


  • Various Expression-Augmenting DNA Elements Benefit from STAR-Select, a Novel High Stringency Selection System for Protein Expression

    by Arie P. Otte, Ted H. J. Kwaks, R.J.M. Vanblokland, Richard G. A. B. Sewalt, John Verhees, Vincent N. A. Klaren, Tjalling K. Siersma, Hans W. M. Korse, Nannette C. Teunissen, Sara Botschuijver, et al.

    The creation of highly productive mammalian cell lines often requires the screening of large numbers of clones, and even then expression levels are often low. Previously, we identified DNA elements, anti-repressor or STAR elements, that increase protein expression levels. These positive effects of STAR elements are most apparent when stable clones are established under high selection stringency. We therefore developed a very high selection system, STAR-Select, that allows the formation of few but highly productive clones. Here we compare the influence of STAR and other expression-augmenting DNA elements on protein expression levels in CHO-K1 cells. The comparison is done in the context of the often-used cotransfection selection procedure and in the context of the STAR-Select system. We show that STAR elements, as well as MAR elements induce the highest protein expression levels with both selection systems. Furthermore, in trans cotransfection of multiple copies of STAR and MAR elements also results in higher protein expression levels. However, highest expression levels are achieved with the STAR-Select selection system, when STAR elements or MARs are incorporated in a single construct. Our results also show that the novel STAR-Select selection system, which was developed in the context of STAR elements, is also very beneficial for the use of MAR elements.


  • A novel, high stringency selection system allows screening of few clones for high protein expression

    by H J M van Blokland, T H J Kwaks, R G A B Sewalt, J A Verhees, V N A Klaren, T K Siersma, J W M Korse, N C Teunissen, S Botschuijver, C van Mer, et al.